#USA #Philadelphia #Rx-360 #Patient Safety #Dr. Verbois

Dr. S. Leigh Verbois Takes Charge at Rx-360

Rx-360 has announced the appointment of Dr. S. Leigh Verbois as its new Chief Executive Officer, effective July 14, 2026. This pivotal appointment marks an important step in the organization's commitment to reinforcing patient safety while enhancing the security and quality of the global pharmaceutical supply chain.

Dr. Verbois expressed her enthusiasm about taking on this crucial role amidst dynamic changes in the pharmaceutical industry. She stated, "I am thrilled to take on this role during this dynamic time in the pharmaceutical industry. I eagerly await working with the talented Rx-360 team to protect patients through global collaboration across the pharmaceutical sector by optimizing existing capabilities and innovating global supply chain security and integrity.”

With a stellar history of leadership in regulatory science, compliance, and public health, Dr. Verbois's experience aligns perfectly with the mission of Rx-360. Before assuming her new role, she served as the Director at the Office of Drug Security, Integrity, and Response at the U.S. Food and Drug Administration (FDA). There, she directed critical initiatives surrounding pharmaceutical imports, exports, and compliance programs.

As the newly appointed CEO, Dr. Verbois will steer Rx-360 through its next stage of growth. She is expected to focus on enhancing Rx-360’s Joint Audit Program® that offers supplier qualification support services, aiming to tackle emerging risks to pharmaceutical quality and supply chain security. Dr. Kathleen Silva, Rx-360 Board Chair, noted, "As CEO, Leigh will lead Rx-360 into its next phase of growth and impact. Building on our strong foundation, she will focus on evolving Rx-360, the Consortium, and our critical work in supply chain security to better meet the increasingly complex needs of the global pharmaceutical industry.”

Dr. Verbois's tenure at the FDA was marked by various leadership positions that impacted global public health significantly. She notably directed the Office of Global Operations and served as Acting Assistant Commissioner for International Programs. During her time in these roles, she fostered essential international relationships aimed at protecting public health on a global scale.

Dr. Verbois's efforts have addressed urgent issues concerning the accessibility of safe and effective drugs while attempting to mitigate global supply chain threats through transparency and collaboration. Her previous role as Senior Director of Global Regulatory and Laboratory Programs at the U.S. Pharmacopoeia further solidified her expertise in these fields.

Under Dr. Verbois's guidance, Rx-360 intends to adopt data-driven insights and artificial intelligence to refine their assessments and foster innovative industry collaborations focused on positive outcomes. The organization aims to meet rising complexities inherent to pharmaceutical manufacturing and distribution worldwide.

With a strong commitment to advancing quality and regulatory standards, Dr. Verbois's collaborative leadership style and extensive global insight uniquely position her to drive Rx-360's mission forward.

As the healthcare landscape evolves, Rx-360 is poised to play a crucial role in setting new standards for patient safety and pharmaceutical integrity under Dr. Verbois’s leadership. This strategic shift marks a new chapter for Rx-360, and stakeholders across the pharmaceutical supply chain are keenly observing how these developments will unfold in the years to come.